NASDAQ:ICCM - Get Free Report ) dropped 3.3% on Wednesday . The stock traded as low as $1.17 and last traded at $1.17. Approximately 287,875 shares traded hands during mid-day trading, a decline of 52% from the average daily volume of 601,639 shares. The stock had previously closed at $1.21.
Get IceCure Medical alerts:
Sign Up
Analyst Upgrades and Downgrades Several research analysts recently commented on the company. Alliance Global Partners increased their price target on IceCure Medical from $1.90 to $2.90 and gave the company a "buy" rating in a report on Wednesday, March 20th. HC Wainwright restated a "buy" rating and issued a $3.00 price target on shares of IceCure Medical in a research note on Tuesday, April 16th.
View Our Latest Stock Report on ICCM
IceCure Medical Price Performance The stock has a fifty day moving average price of $1.23 and a two-hundred day moving average price of $1.14. The firm has a market capitalization of $53.38 million, a P/E ratio of -3.55 and a beta of 0.70. The company has a debt-to-equity ratio of 0.03, a quick ratio of 3.08 and a current ratio of 3.66.
IceCure Medical (NASDAQ:ICCM - Get Free Report ) last issued its earnings results on Wednesday, April 3rd. The company reported ($0.07) EPS for the quarter, beating analysts' consensus estimates of ($0.08) by $0.01. IceCure Medical had a negative return on equity of 86.96% and a negative net margin of 453.76%. The company had revenue of $1.26 million during the quarter. During the same quarter in the previous year, the firm earned ($0.11) earnings per share. Research analysts forecast that IceCure Medical Ltd will post -0.28 EPS for the current year.
IceCure Medical Company Profile (
Get Free Report )
IceCure Medical Ltd, a commercial stage medical device company, engages in the research, development, and commercialization of medical devices for cryoablation (freezing) of tumors in the human body. It offers ProSense system, a single probe system for the treatment of breast tumors; and IceSense3 system for ablation indications to urology, oncology, dermatology, gynecology, general surgery, thoracic surgery, and proctology.
Further Reading Before you consider IceCure Medical, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and IceCure Medical wasn't on the list.
While IceCure Medical currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Click the link below to see which companies made the list.
Get This Free Report
